Vision-related quality of life in spondyloarthritis patients with acute anterior uveitis on golimumab: the GO-VISION study.

Objectives: Acute anterior uveitis (AAU) associated with spondyloarthritis (SpA) is a common extra-articular manifestation, significantly impacting the health-related quality of life (HRQoL). The GO-VISION aimed to evaluate the effects of GOL on visual related (VR) and HRQoL, as well as health-related work productivity (HRWP), in individuals diagnosed with SpA and a history of SpA-AAU.

Methods: This prospective, multicentre study included 20 SpA patients with recent SpA-AAU, treated with GOL and followed for 48 weeks. Data from the 2 years before and 48 weeks after GOL initiation were analysed to assess flare rates. QoL was evaluated using three standardised questionnaires: the National Eye Institute Visual Functioning Questionnaire-25 (NEI VFQ-25), the Short-Form 36 questionnaire (SF-36), and the EuroQol five-dimension scale questionnaire (EQ-5D). Additionally, the impact on HRWP was also studied. The differences between baseline, 24 and 48 weeks were assessed using a one-way repeated measures ANOVA.

Results: Among 20 patients (55% male, 75% tumour necrosis factor-inhibitors (TNFi)-naive, mean age 45.2), AAU flares decreased from 50 in 2 years pre-GOL to 2 during treatment, reducing the incidence rate from 1.82 to 0.10 per 100 patient-years (p<0.01). Significant improvements were seen in NEI VFQ-25 total score (71.85-90.10), EQ index (0.74-0.89), SF-36 physical/mental scores (39.89/49.95 to 60.09/65.86), and hours lost to uveitis (4 to 0; all p<0.02). Two patients experienced mild TNFi-related adverse events.

Conclusions: GO-VISION suggests the effectiveness of GOL in preventing SpA-AAU flares, improving HRQoL, and enhancing productivity, highlighting the importance of patient-reported outcomes.